CoChat

Efficacy and limitations of senolysis in atherosclerosis

Open access

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

Aims: Traditional markers of cell senescence including p16, Lamin B1, and senescence-associated beta galactosidase (SAβG) suggest very high frequencies of senescent cells in atherosclerosis, while their removal via ‘senolysis’ has been reported to reduce atherogenesis. However, selective killing of a variety of different cell types can exacerbate atherosclerosis. We therefore examined the specificity of senescence markers in vascular smooth muscle cells (VSMCs) and the effects of genetic or pharmacological senolysis in atherosclerosis. Methods and results: We examined traditional senescence markers in human and mouse VSMCs in vitro, and in mouse atherosclerosis. p16 and SAβG increased and Lamin B1 decreased in replicative senescence and stress-induced premature senescence (SIPS) of cultured human VSMCs. In contrast, mouse VSMCs undergoing SIPS showed only modest p16 up-regulation, and proliferating mouse monocyte/macrophages also expressed p16 and SAβG. Single cell RNA-sequencing (scRNA-seq) of lineage-traced mice showed increased p16 expression in VSMC-derived cells in plaques vs. normal arteries, but p16 localized to Stem cell antigen-1 (Sca1)+ or macrophage-like populations. Activation of a p16-driven suicide gene to remove p16+ vessel wall- and/or bone marrow-derived cells increased apoptotic cells, but also induced inflammation and did not change plaque size or composition. In contrast, the senolytic ABT-263 selectively reduced senescent VSMCs in culture, and markedly reduced atherogenesis. However, ABT-263 did not reduce senescence markers in vivo, and significantly reduced monocyte and platelet counts and interleukin 6 as a marker of systemic inflammation. Conclusions: We show that genetic and pharmacological senolysis have variable effects on atherosclerosis, and may promote inflammation and non-specific effects respectively. In addition, traditional markers of cell senescence such as p16 have significant limitations to identify and remove senescent cells in atherosclerosis, suggesting that senescence studies in atherosclerosis and new senolytic drugs require more specific and lineage-restricted markers before ascribing their effects entirely to senolysis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cvr/cvab208

Cites

47 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical Abstract Effects of p16-induced genetic senolysis or ABT-263 drug-induced senolysis on atherosclerosis.
Graphical Abstract Effects of p16-induced genetic senolysis or ABT-263 drug-induced senolysis on atherosclerosis.CC BY · PubMed Central
Figure 1 Senescence markers in primary human and mouse VSMCs undergoing senescence. (A) % EdU+ in cultured human VSMCs (Control), after 24h treatment with 500 nM doxorubicin (Dox 1d), after an additional 21 days recovery in control conditions (control 21d) or after doxorubicin (Dox 1d+ 21d), or at replicative senescence (RS). (B–D) mRNA levels of Lamin B1, p16, and p21 in cell populations described in (A) relative to control (1d) cells. (E) Western blot for Lamin B1, p16, p21, and p53 for cells treated in (A). n = 6–8 human VSMC isolates. (F and G) EdU+ % (F) or SAβG+ % (G) of mouse p16-3MR VSMCs treated increasing concentrations of Doxorubicin for 1 day followed by 7 days recovery vs. vehicle control. (I–K) qPCR for Lamin B1, IL6, p16, or p21 mRNA expression for cells treated in (F). (L) Western blot of mouse cells as treated in (F) for Lamin B1, p16, or p21. n = 3–8 mouse VSMC isolates. Data are means (SD), one-way ANOVA with correction for multiple comparisons (A) or unpaired Student’s t-test vs. Control 1d (B–D) or vs. Vehicle (Dox 0 nM) (F–K).
Figure 1 Senescence markers in primary human and mouse VSMCs undergoing senescence. (A) % EdU+ in cultured human VSMCs (Control), after 24h treatment with 500 nM doxorubicin (Dox 1d), after an additional 21 days recovery in control conditions (control 21d) or after doxorubicin (Dox 1d+ 21d), or at replicative senescence (RS). (B–D) mRNA levels of Lamin B1, p16, and p21 in cell populations described in (A) relative to control (1d) cells. (E) Western blot for Lamin B1, p16, p21, and p53 for cells treated in (A). n = 6–8 human VSMC isolates. (F and G) EdU+ % (F) or SAβG+ % (G) of mouse p16-3MR VSMCs treated increasing concentrations of Doxorubicin for 1 day followed by 7 days recovery vs. vehicle control. (I–K) qPCR for Lamin B1, IL6, p16, or p21 mRNA expression for cells treated in (F). (L) Western blot of mouse cells as treated in (F) for Lamin B1, p16, or p21. n = 3–8 mouse VSMC isolates. Data are means (SD), one-way ANOVA with correction for multiple comparisons (A) or unpaired Student’s t-test vs. Control 1d (B–D) or vs. Vehicle (Dox 0 nM) (F–K).CC BY · PubMed Central
Figure 2 p16/Cdkn2a is detected in VSMCs in mouse atherosclerotic plaques. (A and B) UMAP plots showing scRNA-seq profiles of unsorted aortic cells from Myh11CreERt2+/Confetti+ mice (A), or sorted Confetti+ VSMCs from atherosclerotic plaque and media of fat-fed Myh11CreERt2/Confetti+/ApoE−/− mice (B). Log-transformed expression levels of Myh11 and p16/Cdkn2a are shown alongside e-Cadherin/Cdh5 and Pdgfrα (A) or Cd68 and Ly6a/Sca1 (B) using a scale from white to dark red. Insets show high power regions of clusters 6, 8, and 9 and expression of p16 in (B). Feature plots show log-normalized expression levels. (C) % cells in each cluster with detectable expression of p16/cdkn2a after 14 weeks or 18 weeks or high-fat feeding, or combined.
Figure 2 p16/Cdkn2a is detected in VSMCs in mouse atherosclerotic plaques. (A and B) UMAP plots showing scRNA-seq profiles of unsorted aortic cells from Myh11CreERt2+/Confetti+ mice (A), or sorted Confetti+ VSMCs from atherosclerotic plaque and media of fat-fed Myh11CreERt2/Confetti+/ApoE−/− mice (B). Log-transformed expression levels of Myh11 and p16/Cdkn2a are shown alongside e-Cadherin/Cdh5 and Pdgfrα (A) or Cd68 and Ly6a/Sca1 (B) using a scale from white to dark red. Insets show high power regions of clusters 6, 8, and 9 and expression of p16 in (B). Feature plots show log-normalized expression levels. (C) % cells in each cluster with detectable expression of p16/cdkn2a after 14 weeks or 18 weeks or high-fat feeding, or combined.CC BY · PubMed Central
Figure 3 GCV treatment of p16-3MR mice does not affect atherosclerosis, but induces inflammation. (A) Aortic root plaques in ApoE→ApoE, p16→ApoE, ApoE→p16, or p16→p16 mice + GCV, or p16→p16 mice + saline, stained with Masson’s trichrome, TUNEL, or Mac3. Scale bar = 300 µm. High power inset shows apoptotic cell and nuclear debris from outlined area. (B) Plaque area for mice in (A). (C and D) Number of TUNEL+ cells/aortic root plaque (C) or %Mac3+ cells (D) for mice in (A). (E–G) Relative mRNA expression for p16, IL18, or TNFα in experimental mice. Data are means (SD) n = 5–10 mice. One-way ANOVA with correction for multiple comparisons (B–D) or Kruskal–Wallis H test followed by Dunn’s multiple comparisons test (E–G).
Figure 3 GCV treatment of p16-3MR mice does not affect atherosclerosis, but induces inflammation. (A) Aortic root plaques in ApoE→ApoE, p16→ApoE, ApoE→p16, or p16→p16 mice + GCV, or p16→p16 mice + saline, stained with Masson’s trichrome, TUNEL, or Mac3. Scale bar = 300 µm. High power inset shows apoptotic cell and nuclear debris from outlined area. (B) Plaque area for mice in (A). (C and D) Number of TUNEL+ cells/aortic root plaque (C) or %Mac3+ cells (D) for mice in (A). (E–G) Relative mRNA expression for p16, IL18, or TNFα in experimental mice. Data are means (SD) n = 5–10 mice. One-way ANOVA with correction for multiple comparisons (B–D) or Kruskal–Wallis H test followed by Dunn’s multiple comparisons test (E–G).CC BY · PubMed Central
Figure 4 ABT-263 (Navitoclax) selectively reduces senescent VSMCs. (A and B) Photomicrographs (A) or quantification (B) of mouse VSMCs stained for SAβG, as replicating control cells or after dox1 + 7 days treatment, or each group ±1 µM ABT-263 treatment for 48 h. (C) Western blot and quantification for p16 in cells treated in (A and B). (D) Fold change in mRNA expression compared with control replicating cells for p16 and a range of SASP cytokines against the housekeeping gene HMBS. Data are means (SD), n = 4–5. Unpaired Student’s t-test. (E) Mouse macrophages cultured for 28 days, then treated with 1 µM ABT-263 for 48 h and stained for SAβG. Data are means (SD), n = 3. Unpaired Student’s t-test.
Figure 4 ABT-263 (Navitoclax) selectively reduces senescent VSMCs. (A and B) Photomicrographs (A) or quantification (B) of mouse VSMCs stained for SAβG, as replicating control cells or after dox1 + 7 days treatment, or each group ±1 µM ABT-263 treatment for 48 h. (C) Western blot and quantification for p16 in cells treated in (A and B). (D) Fold change in mRNA expression compared with control replicating cells for p16 and a range of SASP cytokines against the housekeeping gene HMBS. Data are means (SD), n = 4–5. Unpaired Student’s t-test. (E) Mouse macrophages cultured for 28 days, then treated with 1 µM ABT-263 for 48 h and stained for SAβG. Data are means (SD), n = 3. Unpaired Student’s t-test.CC BY · PubMed Central
Figure 5 ABT-263 reduces atherosclerosis, but not local SASP cytokine expression. (A) ORO staining of mouse descending aorta treated with control (vehicle) or ABT-263, and quantification of %ORO area (n = 11–14). Scale bar = 3 mm. (B) Masson’s trichrome histochemistry of aortic root atherosclerotic plaque from mice treated in (A). Panels below show high power view of outlined area. Arrow shows necrotic core. Scale bar = 200 µm. (C–E) Aortic root plaque area/total area (C) Cap area (D), or Core area (E) for mice in (A). n = 11–13. (F) qPCR for relative expression of p16 or SASP cytokines in aortic arches of experimental mice against the housekeeping gene HMBS (n = 7). Data are means (SD), n = 10. Unpaired Student’s t-test (A, C–E) or Mann–Whitney U test (F).
Figure 5 ABT-263 reduces atherosclerosis, but not local SASP cytokine expression. (A) ORO staining of mouse descending aorta treated with control (vehicle) or ABT-263, and quantification of %ORO area (n = 11–14). Scale bar = 3 mm. (B) Masson’s trichrome histochemistry of aortic root atherosclerotic plaque from mice treated in (A). Panels below show high power view of outlined area. Arrow shows necrotic core. Scale bar = 200 µm. (C–E) Aortic root plaque area/total area (C) Cap area (D), or Core area (E) for mice in (A). n = 11–13. (F) qPCR for relative expression of p16 or SASP cytokines in aortic arches of experimental mice against the housekeeping gene HMBS (n = 7). Data are means (SD), n = 10. Unpaired Student’s t-test (A, C–E) or Mann–Whitney U test (F).CC BY · PubMed Central
Figure 6 Effects of ABT-263 on peripheral blood counts and overview of effects of senolysis on atherosclerosis. (A–F) Total red blood cell (RBC) and white blood cell (WBC) counts and differential WBC and platelet counts in experimental mice at baseline and end of study after control treatment or with ABT-263. Data are means (SD), n = 12–15, Student’s t-test between baseline and end for each group. (G and H) Schematic of predicted effects of GCV treatment on experimental mice and observed or predicted consequences (G), or of ABT-263 on atherosclerosis and peripheral blood counts (H).
Figure 6 Effects of ABT-263 on peripheral blood counts and overview of effects of senolysis on atherosclerosis. (A–F) Total red blood cell (RBC) and white blood cell (WBC) counts and differential WBC and platelet counts in experimental mice at baseline and end of study after control treatment or with ABT-263. Data are means (SD), n = 12–15, Student’s t-test between baseline and end for each group. (G and H) Schematic of predicted effects of GCV treatment on experimental mice and observed or predicted consequences (G), or of ABT-263 on atherosclerosis and peripheral blood counts (H).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 83

Metadata

Authors
Garrido, A. M., Kaistha, A., Uryga, A. K., Oc, S., Foote, K., Shah, A., Finigan, A., Figg, N., Dobnikar, L., Jørgensen, H., & Bennett, M.
Affiliations
  • University of Cambridge (GB)
  • Babraham Institute (GB)
Corresponding author
Bennett, Martin
Venue
Cardiovascular Research
Published
2021-06-17
Volume
118
Issue
7
Pages
1713-1727
ISSN
  • 0008-6363 (ISSN-L)
  • 1755-3245
OpenAlex
W3171636888
Cited by
83
References
47
Citations by year
2026: 12 · 2025: 21 · 2024: 20 · 2023: 23 · 2022: 6 · 2021: 1
FWCI
7.82
Type
journal article
Language
en
Open access
Locations
  • Cardiovascular Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion)
  • Apollo
Funders
  • British Heart Foundation (grants (RG71070, RG84554))
  • BHF Centre for Research Excellence
  • BHF Oxbridge Centre for Regenerative Medicine, and the National Institute of Health Research Cambridge Biomedical Research Centre
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
Keywords
senolysis, atherosclerosis, cellular senescence, senolytics, navitoclax, p16, senescence-associated β-galactosidase, lamin B1, vascular smooth muscle cells, stress-induced premature senescence, atherosclerotic plaque, monocytes, platelets, inflammation, senescence markers, Sca-1
MeSH terms
Senotherapeutics, Animals, Cells, Cultured, Humans, Inflammation, Muscle, Smooth, Vascular, Biomarkers, Cellular Senescence, Myocytes, Smooth Muscle, Atherosclerosis, Mice, Plaque, Atherosclerotic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and limitations of senolysis in atherosclerosis. https://app.cochat.ai/papers/10.1093/cvr/cvab208
The paper
Garrido, A. M., Kaistha, A., Uryga, A. K., Oc, S., Foote, K., Shah, A., Finigan, A., Figg, N., Dobnikar, L., Jørgensen, H., & Bennett, M. (2022). Efficacy and limitations of senolysis in atherosclerosis. Cardiovascular Research. https://doi.org/10.1093/cvr/cvab208

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.